Uncontrolled diabetes mellitus
Reading Document
Medical Text Search
uncontrolled diabetes mellitus pathophysiology classification diagnosis
Medical Text Search
uncontrolled diabetes mellitus complications management treatment HbA1c
GradeResponse
GradeResponse
Medical Text Search
diabetic ketoacidosis hyperosmolar hyperglycemic state acute complications
Medical Text Search
diabetic nephropathy neuropathy retinopathy microvascular macrovascular complications
Uncontrolled Diabetes Mellitus
Definition & Overview
Diabetes mellitus (DM) is a group of metabolic disorders characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both. "Uncontrolled" DM refers to persistent hyperglycemia despite treatment, typically indicated by HbA1c above the individualized target (commonly >8–9%), or in untreated cases.
(Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus, p. 1; Management of Type 2 Diabetes Mellitus, p. 97)
Classification
| Type | Pathophysiology |
|---|---|
| Type 1 DM | Autoimmune destruction of pancreatic β-cells → absolute insulin deficiency |
| Type 2 DM | Insulin resistance + progressive β-cell dysfunction → relative insulin deficiency |
| Gestational DM | Develops in ~17% of pregnancies; resembles T2DM; resolves post-delivery but is a major T2DM risk factor |
| Other specific types | MODY, drug-induced, pancreatic disease, endocrinopathies |
Why Diabetes Becomes Uncontrolled
- Poor adherence to medications or insulin regimens
- Inadequate dietary control
- Physical inactivity
- Intercurrent illness, infection, or surgery (stress hyperglycemia)
- Incorrect or insufficient pharmacotherapy
- Socioeconomic barriers, health illiteracy
- Psychosocial factors (depression, diabetes distress)
Diagnostic Criteria
| Test | Diabetes | Pre-diabetes |
|---|---|---|
| Fasting plasma glucose | ≥ 126 mg/dL (7.0 mmol/L) | 100–125 mg/dL |
| 2-hr OGTT glucose | ≥ 200 mg/dL (11.1 mmol/L) | 140–199 mg/dL |
| HbA1c | ≥ 6.5% | 5.7–6.4% |
| Random glucose + symptoms | ≥ 200 mg/dL | — |
Diagnosis requires confirmation with a repeat test on a separate day (unless unequivocally symptomatic).
Clinical Presentation
Symptoms of Hyperglycemia
- Classic triad: Polyuria, polydipsia, polyphagia
- Weight loss (especially T1DM)
- Fatigue, blurred vision
- Recurrent infections (UTI, candidiasis, skin infections)
- Slow wound healing
Acute Complications
1. Diabetic Ketoacidosis (DKA) — Primarily T1DM
- Insulin deficiency → lipolysis → ketone production → metabolic acidosis
- Triad: Hyperglycemia (>250 mg/dL) + ketonemia/ketonuria + anion gap metabolic acidosis (pH <7.3, bicarbonate <18 mEq/L)
- Symptoms: N/V, abdominal pain, Kussmaul breathing, fruity breath, altered consciousness
- Treatment: IV fluids, insulin infusion, potassium replacement, treat precipitant
2. Hyperosmolar Hyperglycemic State (HHS) — Primarily T2DM
- Profound hyperglycemia (>600 mg/dL), hyperosmolality (>320 mOsm/kg), minimal ketosis
- Severe dehydration, neurological changes (seizures, coma)
- Treatment: Aggressive fluid resuscitation, gradual insulin, electrolyte correction
3. Hypoglycemia
- Paradoxically common in treated uncontrolled DM during medication adjustment
- BG <70 mg/dL; symptoms: diaphoresis, tremor, palpitations, confusion, seizure
- Treatment: 15-15 rule (15g fast-acting carbs, recheck in 15 min); severe: IV dextrose or glucagon
Chronic Complications
Microvascular
| Complication | Mechanism | Features |
|---|---|---|
| Retinopathy | Advanced glycation end-products, VEGF-mediated neovascularization | Nonproliferative → proliferative; leading cause of blindness in working-age adults |
| Nephropathy | Hyperfiltration → glomerulosclerosis (Kimmelstiel-Wilson nodules) | Microalbuminuria → proteinuria → CKD → ESRD |
| Neuropathy | Sorbitol accumulation, oxidative stress, ischemia | Distal symmetric polyneuropathy, autonomic neuropathy, mononeuropathies |
Macrovascular
- Coronary artery disease — leading cause of death in T2DM; 2–4× increased risk
- Cerebrovascular disease — stroke risk doubled
- Peripheral arterial disease — claudication, non-healing ulcers, diabetic foot
Other
- Diabetic foot — neuropathy + PAD + infection → ulceration → amputation risk
- Dermatological — acanthosis nigricans, necrobiosis lipoidica, diabetic dermopathy
- Cognitive impairment — increased dementia risk
Glycemic Targets (Individualized)
(Management of Type 2 Diabetes Mellitus, p. 97)
| Patient Profile | HbA1c Target |
|---|---|
| Young, healthy, no complications | < 6.5–7.0% |
| Most adults | < 7.0–7.5% |
| Elderly, multiple comorbidities, limited life expectancy | < 8.0–8.5% |
| High hypoglycemia risk | Less stringent (upper bound important) |
Both upper and lower bounds matter — avoid hypoglycemia risk while targeting glycemic control.
Management
Non-Pharmacologic
- Medical nutrition therapy (carbohydrate counting, low glycemic index diet)
- Physical activity (≥150 min/week moderate aerobic exercise)
- Weight loss (especially T2DM; 5–10% body weight improves glycemia significantly)
- Smoking cessation, BP control, lipid management
Pharmacologic — T2DM
| Drug Class | Examples | Key Benefit |
|---|---|---|
| Biguanides | Metformin | First-line; weight neutral/loss, cardiovascular neutral |
| GLP-1 receptor agonists | Semaglutide, liraglutide | Weight loss, CV & renal benefit |
| SGLT-2 inhibitors | Empagliflozin, dapagliflozin | Weight loss, heart failure & CKD benefit |
| DPP-4 inhibitors | Sitagliptin, saxagliptin | Weight neutral, well tolerated |
| Sulfonylureas | Glipizide, glyburide | Hypoglycemia risk, weight gain |
| Thiazolidinediones | Pioglitazone | Insulin sensitizer; fluid retention |
| Insulin | Basal, prandial, premixed | Universal efficacy; required in T1DM |
Pharmacologic — T1DM
- Insulin is mandatory (basal-bolus regimen or continuous subcutaneous insulin infusion/pump)
- Adjuncts: pramlintide, SGLT-2 inhibitors (off-label in some guidelines)
Monitoring
- Self-monitoring of blood glucose (SMBG) — frequency based on regimen
- Continuous glucose monitoring (CGM) — preferred in T1DM; increasingly used in T2DM
- HbA1c — every 3 months if uncontrolled; every 6 months when stable
- Annual: lipid panel, urine albumin-creatinine ratio, eGFR, fundoscopic exam, foot exam, BP
Referral Indications
- Endocrinology: refractory hyperglycemia, complex insulin regimens, T1DM
- Ophthalmology: annual dilated fundus exam
- Nephrology: eGFR <30 or significant proteinuria
- Podiatry/vascular surgery: foot ulcers, PAD
- Diabetes educator / dietitian: education and lifestyle support
Key Takeaway
Uncontrolled DM represents a high-risk state for both acute crises (DKA, HHS) and irreversible organ damage. Management requires individualized glycemic targets, combination pharmacotherapy addressing the underlying pathophysiology, and systematic surveillance for complications. Modern agents (GLP-1 agonists, SGLT-2 inhibitors) provide glycemic control with proven cardiovascular and renal protection, making drug selection an integral part of a holistic treatment strategy.
This is a shared conversation. Sign in to Orris to start your own chat.